Co­hBar, Mor­pho­gen­e­sis link up in re­verse merg­er of two can­cer biotechs

The can­cer-fo­cused Bay Area biotech Co­hBar is en­ter­ing in­to a re­verse merg­er with the pri­vate­ly-held biotech Mor­pho­gen­e­sis.

On Tues­day, Co­hBar and Mor­pho­gen­e­sis

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER